Loading...
RIV Capital Inc.
RIV.CN•CNQ
Healthcare
Drug Manufacturers - Specialty & Generic
CA$0.10
CA$-0.00(-4.76%)

Over the past four quarters, RIV Capital Inc. demonstrated steady revenue growth, increasing from $1.79M in Q1 2023 to $2.14M in Q4 2023. Operating income reached -$5.59M in Q4 2023, maintaining a consistent -261% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$4.33M, reflecting operational efficiency. Net income rose to -$4.99M, with EPS at -$0.04. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan